Navigation Links
Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors

BOSTON, Dec. 2, 2013 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Nancy Thornberry to its Board of Directors. Nancy's exceptional 34-year career at Merck demonstrates the power of her insight, innovation and ability to achieve competitively superior results in the pharmaceutical industry – particularly in diabetes. This makes an excellent match for the development and business opportunity expected with ITCA 650 (a breakthrough once- or twice-yearly GLP-1 for type 2 diabetes that is currently in Phase 3 clinical trials), as well as the Company's longer-term pipeline. Nancy's guidance and input will be of immediate benefit helping Intarcia chart the best course forward for ITCA 650 to bring the product to market and to help realize its full potential to improve treatment outcomes for appropriate patients with type 2 diabetes around the world.

"Nancy is an industry leader and icon of pharmaceutical innovation, having personally led the discovery, and subsequently the global franchise aspects, for a novel diabetes medicine and combinations that are fundamentally improving medical outcomes for type 2 diabetics around the world," said Kurt Graves, Chairman, President and CEO of Intarcia. "It's very exciting to have someone of Nancy's caliber and deep expertise in diabetes and metabolism join our Board and work shoulder-to-shoulder with us as we strive to bring our once-yearly and potentially game-changing medicine, ITCA 650, to patients suffering from type 2 diabetes. Our Board and management team are all extremely excited to have Nancy become our newest member of our Board of Directors."

Nancy Thornberry began her distinguished career at Merck Research Laboratories in 1979 as a Biochemist, and steadily assumed positions of increasing responsibility – distinguishing herself along the way with numerous and significant achievements. Those achievements came early as Nancy provided critical enzymology support to the angiotensin converting enzyme (ACE) inhibitor project for the treatment of hypertension, and multiple other targets.  Her early accomplishments also include the identification of the first caspase, interleukin-1b converting enzyme (ICE/caspase-1), and contributions to the discovery of the target of ezetimibe, the active ingredient in ZETIA™.

In 1999 Nancy became the Director of Enzymology, and then in 2001 the Director of Metabolic Disorders. It was during this same time that the full magnitude of Nancy's contributions became apparent. She initiated the DPP-4 program in 1999, and co-led the team resulting in the discovery of Januvia™ (sitagliptin) in 2001. Sitagliptin is currently the #1 branded oral agent for the treatment of type 2 diabetes, and the largest selling product in Merck history. 

In 2007 Nancy became a Vice President and Worldwide Basic Research Head for Diabetes and Obesity, and then again was promoted in 2009 to SVP and Franchise Head of Diabetes and Obesity. Finally in 2011 Nancy became SVP and Franchise Head of Diabetes and Endocrinology for Merck Research Laboratories. In this role, she was responsible for strategy and pipeline management for R&D in the areas of diabetes, osteoporosis, fertility, and contraception, and numerous programs advanced under her leadership.

In addition to a prolific publishing record, Nancy has been awarded numerous times for her accomplishments, including in 2011 the PhRMA Discoverers Award. She has guest lectured at prestigious venues, as well as chaired many key scientific and medical sessions.

Nancy explained that she was drawn to the Intarcia Board opportunity because of the Company's capabilities and culture of innovation, and her assessment that ITCA 650 has the potential to make a real difference in the lives of patients with type 2 diabetes – Nancy knows very well that many patients around the world still need new treatment alternatives that can provide even better medical control, as well as markedly better compliance rates with their medicines over time. "I am very interested in new medicines that have the potential to be game changers in the treatment of serious diseases, and I see opportunities at Intarcia not only with ITCA 650 but in the Company's longer-term pipeline initiatives.  I look forward to working with the Board and senior leadership to help to advance these programs and create the type of clinical outcomes success that will benefit patients."

About ITCA 650
ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031. ITCA 650 is currently in a global phase 3 clinical trial program called FREEDOM, first phase 3 results are expected in less than one year at the end of 3Q, 2014.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
2. Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
3. Scientists develop way to successfully give nanoparticle therapeutics orally
4. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
5. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
8. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
9. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
10. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
11. Convoy Therapeutics Appoints Clinical Advisory Board
Post Your Comments:
(Date:10/9/2015)... Oct. 9, 2015  Pulmatrix, Inc., (NASDAQ: PULM ) ... investor conferences. th Annual BIO Investor ... (2:00 pm EDT). --> th Annual ... am PDT (2:00 pm EDT). --> Pulmatrix ... Growth Stock Conference on Thursday, October 15, 2015 at 8:30 ...
(Date:10/8/2015)... 2015  Sorrento Therapeutics, Inc. (NASDAQ:  SRNE; Sorrento), ... cancer and associated pain, announced today that Dr. Henry Ji, ... at the Aegis Capital Corporation 2015 Growth Conference ... Corporation 2015 Growth ConferenceDate:Friday, October 9, 2015Time:10:00 to ... The Wynn in Las Vegas, NV , ...
(Date:10/8/2015)... , October 8, 2015 ... .   --> Goldman Small Cap ... the small cap and microcap sectors, announced today ... report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), ... on developing and preparing treatments for cancer and ...
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
Breaking Biology Technology:
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today announced that ... units at an issue price of US $1.20 for gross ... one common share and one half common share purchase warrant. Each whole ... until March 10, 2015 . , ...
... March 10 Bone Biologics, Inc. announced today ... shares from the Musculoskeletal Transplant Foundation (MTF). MTF now ... financing, MTF also provided a line of credit to ... by MTF that have allowed Bone Biologics, Inc. to ...
... ... ... ... ...
Cached Biology Technology:
(Date:9/28/2015)... 28, 2015 CLEAR, the leading ... expedited traveler service is coming to Austin-Bergstrom ... bringing a frictionless experience, serious speed and ... "CLEAR offers our travelers an expedited security ... Jim Smith , Executive Director, Austin-Bergstrom ...
(Date:9/28/2015)... JOSE, Calif. , Sept. 28, 2015 ... of human interface solutions, today announced that Lenovo has ... touch fingerprint sensor, FS4202, for its latest smartphone, the ... secure, password-free access to unlock the device and provide ... The feature-rich Natural ID FS4202 sensor ...
(Date:9/10/2015)... This report provides detailed descriptions of the sensor types ... types that will dominate in the future. Many product ... technology hype curve in the last five years before ... all of them is the prominence of sensor options ... Sensors collect data about the physical and chemical properties ...
Breaking Biology News(10 mins):
... Society today commends President Obama,s decision to sign a ... scientific evidence is used in the development of solutions ... memorandum rightly places science at the forefront of informing ... of solutions to issues such as enhancing energy security, ...
... of proteins, the molecular machines that drive all life, also ... study, in the journal Structure , reveals that after ... of innovation. The active regions of many proteins, called domains, ... host of structures that had never been seen before. This ...
... to treat critical limb ischemia in peripheral arterial ... thwarted by restenosis (the re-narrowing of the artery ... need for repeat treatments and the continued progression ... and amputation. Interventional radiologists have been studying a ...
Cached Biology News:
ma. plate stack height 70mm...
Rotor for four tube-loaded buckets; ma RCF 2550g; sold without buckets...
CQCS kit for etra KR 4i , (other units)....
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
Biology Products: